Welcome to our dedicated page for NVTA news (Ticker: NVTA), a resource for investors and traders seeking the latest updates and insights on NVTA stock.
This page aggregates news and press releases related to Invitae (OTC: NVTA), a medical genetics company that focuses on clinical genetic testing, variant classification, and genomic data research. The news coverage reflects Invitaes role in medical laboratories, health care, and social assistance, as well as its corporate and financial developments.
Company announcements describe Invitae as a provider of genetic information that aims to deliver accurate and actionable results to support medical decision-making. News items include updates on research presented at professional meetings, such as the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting and the American Society of Breast Surgeons Annual Meeting. These stories highlight work on variant reclassification, machine learning models for hereditary cancer and Lynch syndrome genes, and studies of variants of uncertain significance and their impact on clinical management.
Other articles focus on Invitaes technology platforms and data resources, including the Invitae Generation platform and Clinical Variant Modeling, which the company describes as using machine learning and large genomic datasets to improve variant classification. News also covers collaborations with biopharmaceutical partners, such as an agreement with BridgeBio Pharma to use Invitaes rare disease enriched dataset and analytical capabilities for genetics-based drug discovery.
In addition to scientific and product-related updates, the news feed includes major corporate events. These include Invitaes filing for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of New Jersey, its court-supervised sale process, and the selection of Labcorp as the winning bidder to acquire substantially all of the companys assets, subject to approvals. Asset transactions involving specific business lines, such as the transfer of certain reproductive health assets to Natera, also appear in coverage.
Investors, clinicians, and others interested in NVTA can use this page to review historical and ongoing developments in Invitaes research activities, technology initiatives, partnerships, restructuring efforts, and asset sales as reported in public news sources.
Citizen Health has secured $30 million in Series A funding led by 8VC, with participation from Transformation Capital and Headline, bringing total funding to $44 million. The company, founded by former Invitae (NYSE: NVTA) executives, is developing an AI-powered healthcare platform focused on rare disease care.
The platform has built 60 engaged communities across 123 rare and complex conditions, partnering with 70+ patient advocacy groups. Key achievements include a 98.3% patient data sharing rate for research, FDA acceptance of their data for regulatory submission, and collaborations with 10+ pharmaceutical partners.
Citizen Health plans to launch its first AI Advocate version in Q3, alongside a new product for patient advocacy groups, focusing on recruiting AI engineers and expanding partnerships.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
